Blog

Slider

Eagle Biosciences Functional Leptin ELISA Assay Kit was utilized in a clinical study to monitor those with functional leptin deficiency. Circulating leptin levels in the body are crucial for maintaining body weight. This clinical study was developed to test for a valid diagnostic tool to detect functionally leptin in those who have defective leptin receptor binding. To view more information about our Leptin ELISA Assay Kit click here.

Abstract:

Context and aims: Functional leptin deficiency is characterized by high levels of circulating immunoreactive leptin (irLep), but a reduced bioactivity of the hormone due to defective receptor binding. As a result of the fact that affected patients can be successfully treated with metreleptin, it was aimed to develop and validate a diagnostic tool to detect functional leptin deficiency.

Methods: An immunoassay capable of recognizing the functionally relevant receptor-binding complex with leptin was developed (bioLep). The analytical quality of bioLep was validated and compared to a conventional assay for immune-reactive leptin (irLep). Its clinical relevance was evaluated in a cohort of lean and obese children and adults as well as in children diagnosed with functional leptin deficiency and their parents.

Results: In the clinical cohort, a bioLep/irLep ratio of 1.07 (range: 0.80–1.41) was observed. Serum of patients with non-functional leptin due to homozygous amino acid exchanges (D100Y or N103K) revealed high irLep but non-detectable bioLep levels. Upon treatment of these patients with metreleptin, irLep levels decreased, whereas levels of bioLep increased continuously. In patient relatives with heterozygous amino acid exchanges, a bioLep/irLep ratio of 0.52 (range: 0.48–0.55) being distinct from normal was observed.

Conclusions: The new bioLep assay is able to diagnose impaired leptin bioactivity in severely obese patients with a homozygous gene defect and in heterozygous carriers of such mutations. The assay serves as a diagnostic tool to monitor leptin bioactivity during treatment of these patients.

Wabitsch, M., Pridzun, L., Ranke, M., Schnurbein, J. V., Moss, A., Brandt, S., . . . Kratzsch, J. (2017). Measurement of immunofunctional leptin to detect and monitor patients with functional leptin deficiency. European Journal of Endocrinology,176(3), 315-322. doi:10.1530/eje-16-0821

Slider

FGF-23 is a hormone that is secreted by osteoblasts within the bones. This protein works with the kidneys to help regulated levels of phosphate in the blood/serum. The kidney gets rid of excess phosphate by excreting it in urine. When more phosphate is needed, the kidney reabsorb phosphate into the bloodstream. FGF-23 signals the kidneys to stop reabsorbing phosphate into the bloodstream. This fibroblastic growth factor binds to a receptor protein called FGF receptor 1. These receptors span the membrane of kidney cells. The binding of the protein and the receptors stimulates a signal cascade that stops phosphate reabsorption into the bloodstream.


image credit: https://www.kidney-international.org/

Why measure FGF-23?

Phosphate plays a critical role in the formation and growth of bones in children and for maintaining bone strength in adults. An imbalance in levels of FGF-23 in the body causes high or low levels of phosphate in the bloodstream. Low levels of phosphate in the blood can result in hypophosphatemia rickets or osteomalacia, which is a weakening of the bone which can cause bone pain and fractures. High levels of phosphate in the blood can indicate kidney disfunction.

Check out our two kits used for measuring FGF-23:

Slider

 

Mesothelioma is a malignant lung cancer that is commonly associated with previous asbestos exposure. Often it is not diagnosed until too late to treat in a patient. Calretinin has recently been in the spotlight as a potential biomarker for early detection of mesothelioma.

Two recent studies used Eagle Bioscience’s Calretinin ELISA Assay kit analyzing the accuracy of using Calretinin as a prediagnostic technique for mesothelioma:

  • Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population.
    Aguilar-Madrid, Guadalupe, et al. “Biomarkers for Predicting Malignant Pleural Mesothelioma in a Mexican Population .” International Journal of Medical Sciences, vol. 15, no. 9, 2018, pp. 883–891.
  • Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers.
    Johnen, G., Burek, K., Raiko, I., Wichert, K., Pesch, B., Weber, D. G., . . . Brüning, T. (2018). Prediagnostic detection of mesothelioma by circulating calretinin and mesothelin – a case-control comparison nested into a prospective cohort of asbestos-exposed workers. Scientific Reports,8(1).

Learn more about our Calretinin ELISA Assay kit here.

2018 was a big year here at Eagle Biosciences, and 2019 is expected to be even better! We will be making appearances at many tradeshows and conferences this year!

Endo2019
March 23rd-26th
New Orleans, LA
Booth #1930

AACR Annual Meeting
March 29th-April 3rd
Atlanta, GA
Booth #4644

AACC Annual Meeting
August 4th-8th
Anaheim, CA

The Association of Medical Laboratory Immunologists (AMLI) Annual Scientific Meeting
August 16th-19th
Cleveland, OH

American Society for Bone and Mineral Research (ASBMR) Annual Meeting
September 20th-23rd
Orlando, FL

ASN Kidney Week
November 5th-10th
Washington, DC

Medica Tradefair 
November 18th-21st
Düsseldorf, Germany

We’d love to meet you!

If you will be attending any of these events, stop by and say hi! Or set up a meeting if you have any big plans you’d like to talk about

 

Eagle Biosciences, Inc. is excited to collaborate with Austrian biotech Fianostics, to offer a new fluorescence-based detection platform for immunoassays, called FluoBolt™, which enables highly sensitive assays with high reproducibility and reliability. This dramatically improves the informative value of research with biomarkers.

So far, Fianostics FluoBolt™ Metal Enhanced Fluorescence Immunoassays have been developed to detect

What Makes These Assays Different?

Fianostics FluoBolt™ Metal Enhanced Fluorescence Immunoassays have been established to eliminate the complicated processes that come with your standard sandwich ELISA. By using their FluoBolt™ Metal Enhanced Fluorescence Immunoassays, you can expect

  • High Sensitivity!
  • Single Step Assay Procedure!
  • No Enzyme Substrate!
  • Stable Signal over Time!
  • 100% Compatibility with 96-well ELISA Format!

About Fianostics

Fianostics combines scientific and technical expertise in diagnostics with the development of a high-tech detection platform that benefits in reproducibility from the excellent expertise of Sony DADC BioSciences in the production of polymer consumables for the diagnostic industry. Their know-how is not limited to the development of the new detection platform, but we also provide the diagnostic application with the appropriate immunoassays for specific clinical areas. (for research use only in the US)

About Metal Enhanced Fluorescence

Metal Enhanced Fluorescence (MEF) offers the possibility to dramatically increase the analytical sensitivity of systems based on fluorescence detection. MEF is based on the fact that excitation light interacts with the electrons of metal nano–structures thus generating very high electromagnetic fields (Localised Surface Plasmons, LSPs ) Therefore, such structures are also called
”plasmonic structures” and the combination of (e.g, polymeric) support and structure is known as “plasmonic substrate”. These LSPs lead to an increase in emission output of fluorescent molecules (e.g. fluorescently labelled antibodies) when bound to surfaces with suitable nano-metal structures that can enhance the signal more than 100 times.

Hello Loyal Customers!

Our team here at Eagle Biosciences, Inc. are so excited to introduce our new look for you to enjoy! The new EagleBio.com comes chocked-full of new features that will make your browsing and shopping experience far superior to what you’re used to!

  • Speak with one of our team members online when you need help
  • Fast, easy and secure check out
  • Smooth navigation while browsing one of our many unique products

But That’s Not All…

Not only have we made your shopping experience better when you choose to order from Eagle Biosciences, but we are also working with some phenomenal new partners to bring you new and unique products! Here’s a sneak peak…

  • Fianostics FluoBolt™-FIAs : Metal enhanced fluorescence assays that offers a higher sensitivity, single-step alternative to your basic ELISA. Available for detection of Noggin, Asporin, and Periostin! As well as services to test a variety of other markers!
  • osteomiR testing by TAmiRNA : Workflow that detects 11 microRNA associated with bone quality. We will feature osteomiR Test Kit, as well as services that can run your samples for you.
  • New and unique Drug Monitoring Assays

As always, we appreciate your business! Without you we wouldn’t be able to do what we love by providing you the products you need to change the future! Be sure to keep an eye out for more to come.


If you want to see anything from Eagle Biosciences (products, services, etc.) Let us know! We’re here for you!

Eagle Biosciences Histamine ELISA Assay Kit used in a recent study. This kit is part of our Immunology Assay Kit line which is a line of highly sensitive and specific kits used for the detection of a variety of samples in serum, plasma, tissue, urine, and saliva.

Histamine deficiency aggravates cardiac injury through miR-206/216b-Atg13 axis-mediated autophagic-dependant apoptosis

Abstract:

Histamine is a widely distributed biogenic amine involved in the regulation of an array of biological processes. Serum histamine level is markedly elevated in the early stages of acute myocardial infarction, whereas the role it plays remains unclear. Histidine decarboxylase (HDC) is the unique enzyme responsible for histamine production, and cardiac injury is significantly aggravated in HDC knockout mice (HDC−/−), in which histamine is deficient. We also observed that autophagy was highly activated in cardiomyocytes of HDC−/− mice post acute myocardial infarction (AMI), which was abolished by compensation of exogenous histamine. The in vivo and in vitro results showed that acting through histamine 1 receptor, histamine increased miR-206 and miR-216b, which worked in concert to target to Atg13, resulting in the reduction of autophagy activation under hypoxia and AMI condition. Further study revealed that Atg13 interacted with FADD to promote the activation of caspase-8 and cell apoptosis. Taken together, these data unveil a novel intracellular signaling pathway involved in histamine regulating myocardial autophagy and apoptosis under hypoxia and AMI condition, which might help to more comprehensively evaluate the usage of histamine receptor antagonists and to develop new therapeutic targets for myocardial infarction.

Ding, Suling, et al. “Histamine Deficiency Aggravates Cardiac Injury through MiR-206/216b-Atg13 Axis-Mediated Autophagic-Dependant Apoptosis.” Cell Death & Disease, vol. 9, no. 6, 7 June 2018, p. 694., doi:10.1038/s41419-018-0723-6.

Eagle Biosciences announces the expansion of our line of Gastrointestinal Assays to include a Lactoferrin ELISA Assay Kit as well as a TNF-Alpha Stool ELISA Assay Kit. These kits add to our world class line of stool assays that include ZonulinPancreatic ElataseBlastocystis, and NGAL

Lactoferrin ELISA Assay TNF-Alpha ELISA Assay
Size: 1×96 wells Size: 1×96 wells
Sensitivity: 0.369 ng/mL Sensitivity: 10 pg/mL
Incubation: 1.5 hours Dynamic Range: 10-500 pg/mL
Sample: Stool Incubation: 4.5 hours
Size: 15 mg Sample: Plasma, Serum, Stool

What is Lactoferrin and TNF-Alpha?

Lactoferrin is a protein found in a monomer or tetramer, that is involved in iron homeostasis, innate defense against microbial infections, anti-inflammatory activity, regulation of cellular growth and differentiation and protection against cancer. Elevated levels of lactoferrin are associated with Inflammatory Bowel Disease (IBD) such as Ulcerative Colitis (UC) or Crohn’s Disease (CD).

TNF-Alpha’s primary role is the regulation of immune cels. It stimulates apoptotic cell death, cell proliferation, and differentiation, inhibits tumor genesis and viral replication. Elevated levels of TNF-Alpha are found in patients suffering from Crohn’s Disease (CD), Ulcerating Colitis (UC), or Rheumatoid Arthritis (RA).

Eagle Bioscience’s Total Testosterone ELISA Assay Kit was used in a recent study. This kit is part of our line of Steroid Assay Kits which is a line of highly sensitive and specific assays used to detect a variety of samples in serum, plasma, tissue, urine, and saliva.

Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

Background

Prostate cancer patients on androgen deprivation therapy (ADT) experience adverse effects such as lean mass loss, known as sarcopenia, fat gain, and changes in cardiometabolic factors that increase risk of metabolic syndrome (MetS). Resistance training can increase lean mass, reduce body fat, and improve physical function and quality of life, but no exercise interventions in prostate cancer patients on ADT have concomitantly improved body composition and MetS. This pilot trial investigated 12 weeks of resistance training on body composition and MetS changes in prostate cancer patients on ADT. An exploratory aim examined if a combined approach of training and protein supplementation would elicit greater changes in body composition.

Conclusions

A 12-week resistance training intervention effectively improved sarcopenia, body fat %, strength and quality of life in hypogonadal prostate cancer patients, but did not change MetS or physical function. PRO did not offer additional benefit in improving body composition.

Dawson, Jacqueline K., et al. “Impact of Resistance Training on Body Composition and Metabolic Syndrome Variables during Androgen Deprivation Therapy for Prostate Cancer: a Pilot Randomized Controlled Trial.” BMC Cancer, vol. 18, no. 1, 3 Apr. 2018, p. 368., doi:10.1186/s12885-018-4306-9.

Yale Researchers Identify Target for Novel Malaria Vaccine

Yale University

A team of researchers has developed a vaccine against malaria infection targeting a unique protein produced by malaria parasites. Plasmodium macrophage migration inhibitory factor (PMIF) suppresses the infection fighting cells that respond to threats and protect the body against reinfection. PMIF is critical for the completion of the parasite life cycle, specifically the transmission to new hosts. An RNA based vaccine developed by the researchers protects against reinfection in mice. The next step is to develop a vaccine that could be used for individuals who have never been infected with malaria. Researchers also have noted that the PMIF protein has been conserved over various strains of malaria, and therefore it should be nearly impossible for the virus to develop a resistance to the vaccine. 

Read More.